SCYNEXIS, Inc. (SCYX)

Over the past six months, SCYNEXIS's stock has been influenced by several events. In March 2026, the company announced a $40.0 million private placement and completed the acquisition of PXL-770. The full-year 2025 financial results were reported, including the receipt of $24.8 million from GSK in Q4 2025 and recognition of $17.2 million in license agreement revenue. SCY-247 advanced in clinical trials, receiving FDA QIDP and Fast Track Designations. In November 2025, Q3 financial results were reported, and the company announced it would receive $24.8 million from GSK related to the Phase 3 MARIO study. Shareholders experienced dilution with a 104% increase in shares outstanding. The stock price has fluctuated between $0.565 and $1.31, and as of May 8, 2026, it was trading around $0.916, marking a 53.95% increase over the past six months.

Information regarding the specific demand seasonality for SCYNEXIS, Inc. products and services was not available in the provided search results.

SCYNEXIS, Inc. is a U.S.-based biotechnology company focused on developing therapies for difficult-to-treat fungal infections. The company, founded in 1999 and headquartered in Jersey City, New Jersey, operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. Its key products include BREXAFEMME® (ibrexafungerp), approved for treating and preventing recurring vaginal yeast infections; SCY-247, a second-generation fungerp in early-stage clinical trials for serious internal fungal infections; and PXL-770, an AMPK activator under development for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

SCYNEXIS, Inc. is a U.S.-based company with its corporate office located in Jersey City, New Jersey.

SCYNEXIS has enhanced its brand reputation through pipeline advancements and regulatory achievements, including FDA QIDP and Fast Track Designations for SCY-247. The company's commitment to developing innovative therapies for life-threatening infections contributes to a positive reputation. However, the product recall of BREXAFEMME in 2025 could have negatively affected its reputation.

The ownership of SCYNEXIS (SCYX) stock is distributed among institutional investors (11.62% to 15.40%), insiders (6.18%), and public companies and individual investors (78.42%). Major institutional owners include Avidity Partners Management LP, Goldman Sachs Group Inc, Vanguard Group Inc, and BlackRock, Inc.